Piramal Pharma said it began FY27 with stronger revenue and margin expansion, driven by broad-based growth across its contract development and manufacturing, complex hospital generics and consumer healthcare businesses.
For the quarter ended June 30, 2026, consolidated revenue from operations rose 17% year on year to ₹2,270 crore, from ₹1,934 crore in the prior-year period. EBITDA increased 72% to ₹285 crore, lifting EBITDA margin to 12.5% from 8.5%. The company said the improvement reflected higher capacity utilization, operating leverage, pricing discipline and operational excellence.
Piramal Pharma said all three businesses delivered mid-to-high teens revenue growth. In CDMO, growth was supported by healthy order inflows, stronger commercial capabilities and execution across India and overseas sites. The business also benefited from improved biopharma funding, which lifted requests for proposals, although customer decision timelines remain prolonged.
In complex hospital generics, Piramal maintained leadership in key therapies and gained traction in ex-U.S. inhalation anesthesia markets. The company said integration of Kenalog is progressing, with supplies expected to begin from Q2 FY27. The business also held its No. 1 position in the U.S. intrathecal baclofen market.
Consumer healthcare delivered another strong quarter, with power brands growing 23% and e-commerce sales rising 40%. The segment was supported by wider distribution, premiumization, disciplined brand investment and product launches, including a new master brand for its women’s intimate care portfolio.
Chairperson Nandini Piramal said the company is encouraged by the momentum and expects sustained revenue growth and EBITDA expansion through FY27 while remaining agile in a dynamic external environment.
The company also said its Sellersville facility in the U.S. received an Establishment Inspection Report from the U.S. FDA, concluding the inspection and preserving its zero OAI status.